#6

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
NOV 05 2001
TECHNOLOGY CENTER 1600/2900

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 11

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

## U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No.[1] | U.S. Patent Document Number | Kind Code[2] (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | 196 | 6,150,091 | | Pandolfo et al. | 11-21-2000 | |
| | 1 | 6,057,367 | | Stamler et al. | 05-02-2000 | |
| | 2 | 5,958,883 | | Snow | 09-28-1999 | |
| | 3 | 5,955,317 | | Suzuki et al. | 09-21-1999 | |
| | 4 | 5,955,079 | | Mond et al. | 09-21-1999 | |
| | 5 | 5,877,399 | | Hsiao et al. | 03-02-1999 | |
| | 6 | 5,869,093 | | Weiner et al. | 02-09-1999 | |
| | 7 | 5,869,054 | | Weiner et al. | 02-09-1999 | |
| | 8 | 5,854,204 | | Findeis et al. | 12-29-1998 | |
| | 9 | 5,851,996 | | Kline | 12-22-1998 | |
| | 10 | 5,849,298 | | Weiner et al. | 12-15-1998 | |
| | 11 | 5,837,473 | | Maggio e al. | 11-17-1998 | |
| | 12 | 5,786,180 | | Konig et al. | 07-28-1998 | |
| | 207 | 5,780,587 | | Potter | 07-14-1998 | |
| | 13 | 5,753,624 | | McMichael et al. | 05-19-1998 | |
| | 14 | 5,750,349 | | Suzuki et al. | 05-12-1998 | |
| | 197 | 5,744,368 | | Goldgaber et al. | 04-28-1998 | |
| | 211 | 5,736,142 | | Sette et al. | 04-07-1998 | |
| | 15 | 5,733,547 | | Weiner et al. | 03-31-1998 | |
| | 16 | 5,688,651 | | Solomon | 11-18-1997 | |
| | 17 | 5,679,348 | | Nesburn et al. | 10-21-1997 | |
| | 18 | 5,645,820 | | Hafler et al. | 07-08-1997 | |
| | 19 | 5,641,474 | | Hafler et al. | 06-24-1997 | |
| | 20 | 5,641,473 | | Hafler et al. | 06-24-1997 | |
| | 21 | 5,612,486 | | McConlogue et al. | 03-18-1997 | |
| | 22 | 5,605,811 | | Seubert et al. | 02-25-1997 | |
| | 23 | 5,585,100 | | Mond et al. | 12-17-1996 | |
| | 24 | 5,571,500 | | Hafler et al. | 11-05-1996 | |
| | 25 | 5,571,499 | | Hafler et al. | 11-05-1996 | |
| | 175 | 5,441,870 | | Seubert, et al. | 08-15-1995 | |
| | 26 | 5,434,170 | | Andrulis, Jr. | 07-18-1995 | |
| | 27 | 5,387,742 | | Cordell | 02-07-1995 | |
| | 181 | 5,270,165 | | Van Nostrand et al. | 12-14-1993 | |
| | 28 | 5,231,000 | | Majocha et al. | 07-27-1993 | |

OIPE SEP 26 2001 PATENT & TRADEMARK OFFICE

RECEIVED SEP 26 2001 TC 1700

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
NOV 05 2001
TECHNOLOGY CENTER 1600/2900

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 2 of 11

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ Nichols |
| Attorney Docket Number | 15270J-004752US |

O I P E
SEP 24 2001
PATENT & TRADEMARK OFFICE

| | | | | | | |
|---|---|---|---|---|---|---|
| | 29 | 5,220,013 | | Ponte et al. | 06-15-1993 | |
| | 30 | 5,208,036 | | Eppstein et al. | 05-04-1993 | |
| | 31 | 5,192,753 | | McGeer et al. | 03-09-1993 | |
| | 32 | 5,187,153 | | Cordell et al. | 02-16-93 | |
| | 33 | 5,057,540 | | Kensil et al. | 10-15-1991 | |
| | 198 | 5,004,697 | | Pardridge | 04-0201991 | |
| | 34 | 4,666,829 | | Glenner et al. | 05-19-1987 | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document: Office[3] | Number[4] | Kind Code[5] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| | 35 | EP | 911 036 | A2 | | 04-28-1999 | | ☐ |
| | 36 | EP | 868 918 | A2 | | 10-07-1998 | | ☐ |
| | 37 | EP | 863 211 | A1 | | 09-09-1998 | | ☐ |
| | 38 | EP | 845 270 | A1 | | 06-03-1998 | | ☐ |
| | 39 | EP | 782 859 | A1 | | 07-09-1997 | | ☐ |
| | 40 | EP | 683 234 | A1 | | 11-22-1995 | | ☐ |
| | 41 | EP | 666 080 | A1 | | 08-09-1995 | | ☐ |
| | 42 | EP | 652 962 | B1 | | 12-16-1998 | | ☐ |
| | 43 | EP | 639 081 | B1 | | 11-03-1999 | | ☐ |
| | 44 | EP | 613 007 | A2 | | 08-31-1994 | | ☐ |
| | 45 | EP | 594 607 | B1 | | 08-27-1997 | | ☐ |
| | 46 | EP | 561 087 | B1 | | 08-04-1999 | | ☐ |
| | 47 | EP | 526 511 | B1 | | 05-28-1997 | | ☐ |
| | 48 | EP | 506 785 | B1 | | 03-15-2000 | | ☐ |
| | 49 | EP | 451 700 | A1 | | 10-16-1991 | | ☐ |
| | 50 | EP | 440 619 | B1 | | 01-24-1996 | | ☐ |
| | 51 | EP | 359 783 | B1 | | 11-29-1995 | | ☐ |
| | 52 | EP | 276 723 | B1 | | 12-08-1993 | | ☒ |
| | 187 | EP | 783 104 | A1 | | 07-09-1997 | | ☐ |
| | 199 | PCT | 00/77178 | A1 | | 12-21-2000 | | ☐ |
| | 188 | PCT | 00/43049 | A1 | | 07-27-2000 | | ☐ |
| | 53 | PCT | 99/60024 | A1 | | 11-25-1999 | | ☐ |
| | 54 | PCT | 99/60021 | A2 | | 11-15-1999 | | ☐ |
| | 55 | PCT | 99/58564 | A1 | | 11-18-1999 | | ☐ |
| | 56 | PCT | 99/06066 | A2 | | 02-11-1999 | | ☐ |
| | 57 | PCT | 99/27949 | A1 | | 06-10-1999 | | ☐ |

RECEIVED
SEP 26 2001
TC 1700

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 11

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ Nichols |
| Attorney Docket Number | 15270J-004752US |

RECEIVED
NOV 05 2001
TECHNOLOGY CENTER 1600/2900

OIPE
SEP 24 2001
PATENT & TRADEMARK OFFICE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | 58 | PCT | 99/27944 | A1 | | 06-10-1999 | | ☐ |
| | 59 | PCT | 99/27911 | A1 | | 06-10-1999 | | ☐ |
| | 203 | PCT | 99/00150 | A2 | | 01-07-1999 | | ☐ |
| | 60 | PCT | 98/44955 | A1 | | 10-15-1998 | | ☐ |
| | 61 | PCT | 98/07850 | A2 | | 02-26-1998 | | ☐ |
| | 202 | PCT | 97/21728 | A1 | | 06-19-1997 | | ☐ |
| | 62 | PCT | 97/17613 | A1 | | 05-15-1997 | | ☐ |
| | 63 | PCT | 96/39176 | A1 | | 12-12-1996 | | ☐ |
| | 208 | PCT | 96/28471 | A1 | | 09-19-1996 | | ☐ |
| | 64 | PCT | 96/25435 | A1 | | 08-22-1996 | | ☐ |
| | 65 | PCT | 96/18900 | A1 | | 06-20-1996 | | ☐ |
| | 66 | PCT | 95/31996 | A1 | | 11-30-1995 | | ☐ |
| | 200 | PCT | 95/12815 | A1 | | 05-11-1995 | | ☐ |
| | 67 | PCT | 95/11994 | A1 | | 05-04-1995 | | ☐ |
| | 68 | PCT | 95/11311 | A1 | | 04-27-1995 | | ☐ |
| | 69 | PCT | 95/05853 | A1 | | 03-02-1995 | | ☐ |
| | 70 | PCT | 95/04151 | A2 | | 02-09-1995 | | ☐ |
| | 201 | PCT | 94/28412 | A1 | | 12-08-1994 | | ☐ |
| | 71 | PCT | 94/03615 | A1 | | 02-17-1994 | | ☐ |
| | 72 | PCT | 94/01772 | A1 | | 01-20-1994 | | ☐ |
| | 73 | PCT | 93/21950 | A1 | | 11-11-1993 | | ☐ |
| | 74 | PCT | 93/16724 | A1 | | 09-02-1993 | | ☐ |
| | 75 | PCT | 93/15760 | A1 | | 08-19-1993 | | ☐ |
| | 76 | PCT | 93/14200 | A1 | | 07-22-1993 | | ☐ |
| | 205 | PCT | 93/04194 | A1 | | 03-04-1993 | | ☐ |
| | 77 | PCT | 93/02189 | A1 | | 02-04-1993 | | ☐ |
| | 78 | PCT | 92/13069 | A1 | | 08-06-1992 | | ☐ |
| | 79 | PCT | 92/06708 | A1 | | 04-30-1992 | | ☐ |
| | 80 | PCT | 92/06187 | A1 | | 04-16-1992 | | ☐ |
| | 81 | PCT | 91/19810 | A1 | | 12-26-1991 | | ☐ |
| | 82 | PCT | 91/16819 | A1 | | 11-14-1991 | | ☐ |
| | 83 | PCT | 91/12816 | A1 | | 09-05-1991 | | ☐ |
| | 84 | PCT | 91/08760 | A1 | | 06-27-1991 | | ☐ |
| | 85 | PCT | 90/12871 | A1 | | 11-01-1990 | | ☐ |
| | 86 | PCT | 90/12870 | A1 | | 11-01-1990 | | ☐ |
| | 87 | PCT | 89/01343 | A1 | | 02-23-1989 | | ☐ |
| | 88 | PCT | 89/06242 | A1 | | 07-13-1989 | | ☐ |
| | 89 | PCT | 89/06689 | A1 | | 07-27-1989 | | ☐ |
| SG | 90 | PCT | 89/03687 | A1 | | 05-05-1989 | | ☐ |

RECEIVED
SEP 26 2001
TC 1700

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
NOV 05 2001
TECHNOLOGY CENTER 1600/2900

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 4 of 11

| *Complete if Known* | |
|---|---|
| **Application Number** | 09/724,961 |
| **Filing Date** | November 28, 2001 |
| **First Named Inventor** | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1617 |
| Examiner Name | ~~Unassigned~~ Dickens |
| Attorney Docket Number | 15270J-004752US |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | 91 | PCT | 88/10120 | A1 | | 12-29-1988 | | ☐ |
| | 92 | GB | 2 220 211 | A | | 01-04-1990 | | ☐ |
| | 93 | GB | 2 335 192 | A | | 09-15-1999 | | ☐ |

OIPE JC149 SEP 24 2001 PATENT & TRADEMARK OFFICE

RECEIVED
SEP 26 2001
TC 1700

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 5 of 11

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1774~~ 1647 |
| Examiner Name | ~~Unassigned~~ DI Citro |
| Attorney Docket Number | 15270J-004752US |

RECEIVED SEP 26 2001 TC 1700

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 94 | ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995). | ☐ |
| | 95 | Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95). | ☐ |
| | 96 | BAUER et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991). | ☐ |
| | 204 | BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," Eur. J. Immunol. 29:345-354 (1999). | ☐ |
| | 212 | BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992). | ☐ |
| | 176 | BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000). | ☐ |
| | 97 | BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999). | ☐ |
| | 98 | BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990). | ☐ |
| | 99 | BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," Neuron, 19: 939-945 (1997). | ☐ |
| | 100 | BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," Cur. Opin. Genet Develop., 3: 102-109 (1993). | ☐ |
| | 101 | BRICE et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993). | ☐ |
| | 102 | CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993). | ☐ |
| | 213 | CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991). | ☐ |
| | 214 | DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001). | ☐ |
| | 103 | DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995). | ☐ |
| | 104 | ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," J. Neurol. Sciences, 59:341-347 (1983). | ☐ |

OFFICIAL SEP 24 2001 PATENT & TRADEMARK OFFICE TC 1600

RECEIVED NOV 05 2001 TECH CENTER 1600/2900

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 6 of 11

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS SEP 26 2001 |
| Attorney Docket Number | 15270J-004752US |

RECEIVED SEP 26 2001 TC 1700

OIPE SEP 24 2001 JC14 PATENT & TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| | 105 | FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993). | ☐ |
| | 106 | FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996). | ☐ |
| | 107 | FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991). | ☐ |
| | 108 | FLANDERS et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995). | ☐ |
| | 210 | FRIEDLAND et al., ""Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994). | ☐ |
| | 109 | GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(6514): 523-527 (1995). | ☐ |
| | 215 | GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_{1-42}$," Annals of the New York Academy of Science 920:274-84 (2000). | ☐ |
| | 110 | GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992). | ☐ |
| | 111 | GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:1181-1186 (1993). | ☐ |
| | 112 | GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998). | ☐ |
| | 113 | GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, 120(3): 885-890 (1994). | ☐ |
| | 114 | GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984). | ☐ |
| | 115 | GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991). | ☐ |
| | 116 | GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996). | ☐ |
| | 190 | GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," J. Biol. Chem., 270(13):7013-7016 (1995). | ☐ |
| | 117 | GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," Vaccine, 15(12/13): 1341-1343 (1997). | ☐ |
| | 118 | HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993). | ☐ |
| | 119 | HANES et al., "New advances in microsphere-based single-dose vaccines," Advanced Drug Delivery Reviews, 28: 97-119 (1997). | ☐ |

RECEIVED NOV 05 2001 TECHCENTER 1600/2900

| Examiner Signature | | Date Considered | 12-3-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 7 of 11

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

RECEIVED SEP 26 2001 TC 1700

OIPE SEP 24 2001 PATENT & TRADEMARK OFFICE

RECEIVED NOV 05 2001 TECH CENTER 1600/2900

| | | | |
|---|---|---|---|
| | 120 | HARDY, "Amyloid, the presenilins and Alzheimer's disease," TINS, 20(4): 154-159 (1997). | |
| | 121 | HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996). | |
| | 193 | HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993). | |
| | 177 | HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," Science, 289:375 (2000). | |
| | 122 | HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," Science, 274: 99-102 (1996). | |
| | 123 | HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994). | |
| | 124 | HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995). | |
| | 125 | ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989). | ☐ |
| | 192 | IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994). | ☐ |
| | 126 | JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-216 (1982). | ☐ |
| | 216 | JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-378 (1991). | ☐ |
| | 127 | KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992). | ☐ |
| | 183 | KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," Biotechnol. Appl. Biochem., 23:227-230 (1996). | ☐ |
| | 128 | KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991). | ☐ |
| | 195 | KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the βA4 Peptide," Annals of NY Acad. Sci., 777:344-355 (1996). | ☐ |
| | 129 | LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993). | ☐ |
| | 130 | LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990). | ☐ |
| | 131 | LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993). | ☐ |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 8 of 11

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~4771~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

RECEIVED SEP 26 2001 TECH CENTER 1600/2900

OIPE SEP 24 2001 PATENT & TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| | 132 | LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999). | ☐ |
| | 133 | LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). | ☐ |
| | 134 | LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991). | ☐ |
| | 218 | MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). | ☐ |
| | 217 | MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985). | ☐ |
| | 135 | MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). | ☐ |
| | 136 | MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). | ☐ |
| | 137 | MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). | ☐ |
| | 206 | MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). | ☐ |
| | 191 | MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994). | ☐ |
| | 138 | NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," Am. J. Epidemiol., 145(11): 959-969 (June 1, 1997). | ☐ |
| | 139 | New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). | ☐ |
| | 140 | PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996). | ☐ |
| | 141 | PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," Eur. J. Immunol., 25: 3521-3524 (1995). | ☐ |
| | 142 | PRIEELS et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994). | ☐ |
| | 143 | QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991). | ☐ |
| | ~~144~~ | ~~RASO, V.A., Grant application # 1 R43 AG15746.01, (publication date unknown).~~ Improper format | ☐ |
| | 145 | RASO, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (April 2, 1998). | ☐ |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1

RECEIVED NOV 05 2001

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 9 of 11

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1774~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

RECEIVED
NOV 05 2001
TECH CENTER 1600/2900

RECEIVED
SEP 26 2001
TC 1700

OIPE
SEP 24 2002
PATENT & TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| | 146 | ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992). | ☐ |
| | 147 | ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993). | ☐ |
| | 209 | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). | ☐ |
| | 189 | SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1993). | ☐ |
| | 194 | SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994). | ☐ |
| | 178 | SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995). | ☐ |
| | 148 | SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999). | ☐ |
| | 149 | SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000). | ☐ |
| | 150 | SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994). | ☐ |
| | 151 | SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 16(10): 403-409 (1993). | ☐ |
| | 152 | SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease……," Scientific American, pgs. 68-78 (November, 1991). | ☐ |
| | 153 | SELKOE, Dennis J., "In the Beginning...," Nature, 354:432-433 (1991). | ☐ |
| | 154 | SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991). | ☐ |
| | 155 | SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997). | ☐ |
| | 156 | SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 359: 325-327 (1992). | ☐ |
| | 157 | SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992). | ☐ |
| | 158 | SMITS et al., "Prion Protein and Scrapie Susceptibility," Vet. Quart., 19(3): 101-105 (1997). | ☐ |
| | 159 | SOLOMON et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS, 94:4109-4112 (1997). | ☐ |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169033 v1

Please type a plus sign (+) inside this box +

PTO/SB/08B (98-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 10 of 11

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | | |
|---|---|---|---|
| | 160 | SOLOMON et al., "Monoclonal antibodies inhibit in *vitro* fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS, 93:452-455 (1996). | ☐ |
| | 161 | ~~SOLOMON, A., "Pro-Rx (Protein Therapeutics), University of Tennessee Medical Center (publication date unknown).~~ | ☐ |
| | 162 | ~~SOLOMON, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel (publication date unknown).~~ | ☐ |
| | 182 | SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996). | ☐ |
| | 184 | SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997). | ☐ |
| | 185 | SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996). | ☐ |
| | 186 | ~~SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv, Israel (publication date unknown).~~ | ☐ |
| | 179 | SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996). | ☐ |
| | 163 | STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against *Plasmodium Falciparum* Malaria", N. Engl. J. Med., 336(2): 86-91 (1997). | ☐ |
| | 164 | STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997). | ☐ |
| | 165 | TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). | ☐ |
| | 166 | TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994). | ☐ |
| | 167 | VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). | ☐ |
| | 168 | VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). | ☐ |
| | 169 | WALKER et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). | ☐ |
| | 180 | WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998). | ☐ |
| | 170 | WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-824 (2000). | ☐ |
| | 171 | WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). | ☐ |



| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 11 of 11

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | ~~1771~~ 1647 |
| Examiner Name | ~~Unassigned~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | | |
|---|---|---|---|
| | 172 | WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin. Neurobiol., 7: 695-700 (1997). | ☐ |
| | 219 | WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," Proc. Natl. Acad. Sci. USA, 82:8729-8732 (1985). | ☐ |
| | 173 | WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS, 94: 1550-1555 (1997). | ☐ |
| | ~~174~~ | ~~Human Immunology & Cancer Program brochure, from The University of Tenessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).~~ | ☐ |



| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#11

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 6

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | Turner, Sharon |
| Attorney Docket Number | 15270J-004752US |

RECEIVED
2002 AUG 27 PM 2:06
OFFICE OF PETITIONS

## U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No.[1] | U.S. Patent Document Number | Kind Code[2] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | 267 | 6,294,171 | B2 | McMichael | 09-25-2001 | |
| | 234 | 6,284,221 | B1 | Schenk, et al. | 09-04-2001 | |
| | 300 | 2001/0018053 | A1 | McMichael | 08-30-2001 | |
| | 230 | 6,262,335 | B1 | Hsiao et al. | 07-17-2001 | |
| | 231 | 6,114,133 | | Seubert et al. | 09-05-2000 | |
| | 221 | 5,989,566 | | Cobb et al. | 11-23-1999 | |
| | 284 | 5,231,170 | | Averback | 07-27-1993 | |
| | ~~242~~ | ~~60/168,594~~ | | ~~Challiour et al.~~ | ~~N/A~~ | |
| | ~~282~~ | ~~60/169,687~~ | | ~~Chain~~ | ~~N/A~~ | |
| | ~~295~~ | ~~60/184,601~~ | | ~~Holtzman et al.~~ | ~~N/A~~ | |
| | ~~299~~ | ~~60/186,295~~ | | ~~Rasmussen et al.~~ | ~~N/A~~ | |
| | ~~290~~ | ~~60/254,465~~ | | ~~Holtzman et al.~~ | ~~N/A~~ | |
| | ~~287~~ | ~~60/254,408~~ | | ~~Holtzman et al~~ | ~~N/A~~ | |
| | ~~283~~ | ~~09/441,140~~ | | ~~Solomon et al.~~ | ~~N/A~~ | |

RECEIVED
SEP 0 3 2002
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document Office[3] | Number[4] | Kind Code[5] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| | 243 | PCT | 01/39796 | A2 | | 06-07-2001 | | |
| | 298 | PCT | 01/42306 | A2 | | 06-14-2001 | | |
| | 301 | PCT | 01/62284 | A2 | | 03-01-2000 | | |
| | 294 | PCT | 01/62801 | A2 | | 08-30-2001 | | |
| | 240 | PCT | 00/43039 | A1 | | 07-27-2000 | | |
| | 227 | PCT | 95/11008 | A2 | | 04-27-1995 | | |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1
PA3242256 v2
PA 3147648 v21

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 2 of 6

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | Turner, Sharon |
| Attorney Docket Number | 15270J-004752US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| ST | 228 | BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992). | |
| | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET. | |
| | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-414B (1992). | |
| | 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002. | |
| ST | 266 | CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2000). | |
| | 222 | ~~Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)~~ improper format | |
| ST | 302 | CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999). | |
| | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000). | |
| | 286 | CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994). | |
| | 287 | COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993). | |
| ST | 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998). | |
| | 220 | ~~Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water. Derwent File 351: Derwent WPI database. (Publication date unknown.)~~ improper format | |
| ST | 288 | DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001). | |
| ST | 225 | Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002). | |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1

PA3242256 v2

PA 3147648 v21

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 6

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | Turner, Sharon |
| Attorney Docket Number | 15270J-004752US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 226 | Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002). | |
| | 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm, Sci., 22:2-3 (2001). | |
| | 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001). | |
| | 247 | FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000). | |
| | 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998). | |
| | 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999). | |
| | 244 | FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000). | |
| | 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). | |
| | 251 | GARDAELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990). | |
| | 252 | GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999). | |
| | 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998). | |
| | 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," Immunology, 93:149-153 (1998). | |
| | 237 | GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949). | |
| | 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000). | |
| | 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992). | |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1
PA3242256 v2
PA 3147648 v 21

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 4 of 6

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | Turner, Sharon |
| Attorney Docket Number | 15270J-004752US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995). | |
| | 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993). | |
| | 236 | HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991). | |
| | 256 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," Lab. Invest., 57:446-449 (1987). | |
| | 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997). | |
| | 258 | KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995). | |
| | 259 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. in Chemical Biology, 1:260-267 (1997). | |
| | 260 | LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000). | |
| | 261 | MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994). | |
| | 263 | MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $Aβ_{42(43)}$," Annals of Neurology, 40:149-156 (1996). | |
| | 262 | MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995). | |
| | 264 | McGeer, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992). | |
| | 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998). | |
| | 265 | Mena, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995). | |
| | 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989). | |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1
PA3242256 v2
PA 3147648 v 21

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 5 of 6

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | Turner, Sharon |
| Attorney Docket Number | 15270J-004752US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 250 | NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995). | |
| | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995). | |
| | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-252 (1998). | |
| | 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965). | |
| | 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987). | |
| | 232 | PETERSON, et al., " Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996). | |
| | 269 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1996). | |
| | 304 | ~~RASO, V.A., Grant application # 1 R43 AG15746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).~~ improper format | |
| | 279 | SAITO et al., "Vector-mediated delivery of $^{125}$I-labeled β-amyloid peptide Ab$^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ$^{1-40}$ vector complex," PNAS USA, 92:10227-10231 (1995). | |
| | 278 | SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," Sapporo Med. J., 60:309-320 (1991). | |
| | 277 | SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997). | |
| | 270 | SCHENK, et al., "β-peptide immunization," Arch. Nuerol., 57:934-936 (2000). | |
| | 271 | ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999). | |
| | 272 | SZENDREI, et al., "The effects of aspartic acid-bond isomerization on *in vitro* properties of the amyloid β-peptide as modeled with *N*-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996). | |
| | 273 | THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000). | |

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1
PA3242256 v2
PA 3147648 v 21

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 6 of 6

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | Turner, Sharon |
| Attorney Docket Number | 15270J-004752US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 276 | TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996). | |
| | 274 | WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). | |
| | 223 | ~~Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep.; 70(24); 56. (Publication date unknown).~~ improper format | |
| | 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). | |
| | 292 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). | |
| | 290 | YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001). | |

RECEIVED
SEP 0 3 2002
TECH CENTER 1600/2900

| Examiner Signature | | Date Considered | 12-5-02 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1
PA3242256 v2
PA 3147648 v 21

#15

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 13

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sheron Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

## U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No.[1] | Document Number: Number Kind Code[2] (*If known*) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|
| GN | 326 | 2002/0136718 A1 | 09-26-2002 | Raso | |
| | 325 | 2001/0102261 A1 | 08-01-2002 | Raso | |
| | 306 | 6,417,178 B1 | 07-09-2002 | Klunk et al. | |
| | 267 | 6,294,171 B2 | 09-25-2001 | McMichael | |
| | 234 | 6,284,221 B1 | 09-04-2001 | Schenk, et al. | |
| | 300 | 2001/0018053 A1 | 08-30-2001 | McMichael | |
| | 230 | 6,262,335 B1 | 07-17-2001 | Hsiao et al. | |
| | 305 | 09/724,842 | 11-28-2000 | Chalifour et al. | |
| | 231 | 6,114,133 | 09-05-2000 | Seubert et al. | |
| | 221 | 5,989,566 | 11-23-1999 | Cobb et al. | |
| | 283 | 09/441,140 | 11-16-1999 | Solomon et al. | |
| | 321 | 5,837,672 | 11-17-1998 | Schenk et al. | |
| | 320 | 5,593,846 | 01-14-1997 | Schenk et al. | |
| GN | 284 | 5,231,170 | 07-27-1993 | Averback | |
| | ~~242~~ | ~~60/168,594~~ | ~~N/A~~ | ~~Chalifour et al.~~ | |
| | ~~282~~ | ~~60/169,687~~ | ~~N/A~~ | ~~Chain~~ | |
| | ~~295~~ | ~~60/184,601~~ | ~~N/A~~ | ~~Holtzman et al.~~ | |
| | ~~296~~ | ~~60/254,465~~ | ~~N/A~~ | ~~Holtzman et al.~~ | |
| | ~~297~~ | ~~60/254,498~~ | ~~N/A~~ | ~~Holtzman et al.~~ | |
| | ~~299~~ | ~~60/186,295~~ | ~~N/A~~ | ~~Rasmussen et al.~~ | |

CONSIDERED; DO NOT PRINT

| Examiner Signature | | Date Considered | 4/29/2003 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 2 of 13

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sheron Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document: Country Code[3] | Foreign Patent Document: Number[4] | Foreign Patent Document: Kind Code[5] (*if known*) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| GJN | 294 | WO | 01/62801 | A2 | 08-30-2001 | | | |
| | 301 | WO | 01/62284 | A2 | 03-01-2000 | | | |
| | 298 | WO | 01/42306 | A2 | 06-14-2001 | | | |
| | 243 | WO | 01/39796 | A2 | 06-07-2001 | | | |
| | 322 | WO | 00/72880 | A2, A3 | 12-07-2000 | | | |
| | 323 | WO | 00/72876 | A2, A3 | 12-07-2000 | | | |
| | 324 | WO | 00/72870 | A1 | 12-07-2000 | | | |
| | 240 | WO | 00/43039 | A1 | 07-27-2000 | | | |
| | 331 | WO | 99/06545 | A2 | 11-02-1999 | | | |
| GJN | 227 | WO | 95/11008 | A2 | 04-27-1995 | | | |

| Examiner Signature | GJN | Date Considered | 4/29/2003 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| GW | 228 | BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992). | |
| | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET. | |
| | 327 | CAMERON, "Recent Advances in Transgenic Technology," Molecular Biotechnology, 7:253-265 (1997). | |
| GW | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-414B (1992). | |
| | ~~224~~ | ~~Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002.~~ | |
| GW | 266 | CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2000). | |
| GW | ~~222~~ | ~~Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)~~ | |

| Examiner Signature | | Date Considered | 4/29/2003 |
|---|---|---|---|

[1] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 4 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | | |
|---|---|---|---|
| CW | 307 | CHEN, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408(6815):975-9 (2000). | |
| | 332 | CHEN, et al., "Neurodegenerative Alzheimer-like pathology in PDAPP, 717V→F transgenic mice," Progress in Brain Research, Van Leeuwen et al. Eds, 117:327-337 (1998). | |
| | 302 | CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999). | |
| | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000). | |
| | 333 | CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," PNAS, 97(2):571-576 (2000) | |
| | 286 | CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994). | |
| | 287 | COSTA et.al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993). | |
| CW | 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998). | |

| Examiner Signature | | Date Considered | 4/29/2003 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 5 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| | ~~220~~ | ~~Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)~~ |
| CJ | 318 | DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001). |
| | 288 | DUMERY et al., "β-Amyloid protein aggregation; its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-86 (2001). |
| | 225 | Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002). |
| | 226 | Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002) |
| | 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm. Sci., 22:2-3 (2001). |
| | 328 | FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). |
| | 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001). |
| GD | 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 6 of 13

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ Nichols |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| CW | 247 | FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000). |
| | 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998). |
| | 244 | FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000). |
| | 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," In Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). |
| | 251 | GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990). |
| | 252 | GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999). |
| | 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998). |
| CW | 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," Immunology, 93:149-153 (1998). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 7 of 13

| Complete if Known | |
|---|---|
| Application Number | 09/724,981 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| CJW | 237 | GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949). |
| | 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000). |
| | 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992). |
| | 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995). |
| | 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993). |
| | 236 | HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991). |
| | 256 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," Lab. Invest., 57:446-449 (1987). |
| | 308 | JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408(6815):979-82 (2000). |
| CJW | 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

[1] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 8 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sheron Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| CDS | 334 | JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," Molecular Microbiology, 5(7):1755-1767 (1991). |
| | 258 | KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995). |
| | 259 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. in Chemical Biology, 1:260-267 (1997). |
| | 260 | LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000). |
| | 261 | MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994). |
| | 263 | MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $Aβ_{42(43)}$," Annals of Neurology, 40:149-156 (1996). |
| | 262 | MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995). |
| CDS | 335 | MASLIAH et al., "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," PNAS, 98(21):12245-12250 (2001). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

[1]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 9 of 13

| Complete if Known | |
|---|---|
| Application Number | 09/724,981 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | | |
|---|---|---|---|
| CR | 309 | MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 77(4):1081-132 (1997). | |
| | 264 | MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992). | |
| | 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998). | |
| | 265 | MENA, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995). | |
| | 310 | MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 4(2):77-85 (2000). | |
| | 311 | MORGAN, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):982-5 (2000). | |
| | 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989). | |
| | 250 | NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995). | |
| CR | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995). | |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 10 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| CW | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-252 (1998). |
| | 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965). |
| | 329 | NIEMANN, "Transgenic farm animals get off the ground;" Transgenic Research 7:73-75 (1998). |
| | 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987). |
| | 336 | PERUTZ et al., "Amyloid fibers are water-filed nanotubes," PNAS, 99(8):5591-5595 (2002). |
| | 232 | PETERSON, et al., " Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996). |
| CW | 269 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1996). |
| | ~~304~~ | ~~RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).~~ |
| CW | 279 | SAITO et al., "Vector-mediated delivery of $^{125}$I-labeled β-amyloid peptide Ab$^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ$^{1-40}$ vector complex," PNAS USA, 92:10227-10231 (1995). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 11 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sheron Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| CPO | 278 | SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," Sapporo Med. J., 60:309-320 (1991). |
| | 277 | SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997). |
| | 312 | SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 20(11):679-81 (2001). |
| | 270 | SCHENK, et al., "β-peptide immunization," Arch. Nuerol., 57:934-936 (2000). |
| | 313 | SELKOE, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8(11):447-53 (1998). |
| | 330 | SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," Arterioscler Thromb Vasc Biol., 20:1425-1429 (2000). |
| | 314 | SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000). |
| | 315 | SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 920:206-8 (2000). |
| | 337 | SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," Trends in Biotech, 18(1):34-39 (2000). |
| CPO | 319 | SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2(8):595-8 (2001). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 12 of 13

| Complete if Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| CBV | 316 | SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998). |
| | 271 | ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999). |
| | 338 | STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," The Journal of Neuroscience, 22(17):7380-7388 (September 1, 2002). |
| | 272 | SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996). |
| | 339 | TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," PNAS, 92:4299-4303 (1995). |
| | 273 | THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000). |
| | 276 | TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996). |
| CBV | 317 | VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA-Cell Biol. (11):713 21 (2001). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 13 of 13

| Complete If Known | |
|---|---|
| Application Number | 09/724,961 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | ~~Sharon Turner~~ NICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | | |
|---|---|---|
| | 274 | WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). |
| | ~~223~~ | ~~WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use In Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)~~ |
| | 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). |
| | 292 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998). |
| | 290 | YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001). |

| Examiner Signature | | Date Considered | 4/29/03 |
|---|---|---|---|

[1]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284621 v1